Open AccessChronic Myeloid Leukemia After Treatment with 131I for Thyroid Carcinoma
Author(s) -
Kang-Ling Wang,
LiangYu Lin,
PoMin Chen,
Han-Chieh Lin
Publication year - 2005
Publication title -
journal of the chinese medical association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.535
H-Index - 42
eISSN - 1728-7731
pISSN - 1726-4901
DOI - 10.1016/s1726-4901(09)70213-8
Subject(s) - medicine , thyroid carcinoma , myeloid leukemia , thyroid , radioactive iodine , papillary carcinoma , radioiodine therapy , radiation therapy , complication , oncology , carcinoma , chronic lymphocytic leukemia , leukemia , pathology
A 27-year-old male developed Philadelphia chromosome-positive chronic myeloid leukemia (CML) 13 years after a first dose of radioiodine (131I) therapy for papillary thyroid carcinoma. He had received a cumulative 131I dose of 670 mCi, in 8 divided doses over 8 years, up to April 1998, for ablation of 131I avid tissues over the anterior neck region. The leukemogenic potential of radioactive iodine has been pointed out by many authors, but most reported cases have been acute leukemias. A literature review disclosed only 9 cases similar to ours. At present, there is no evidence to prove whether the development of CML after thyroid carcinoma represents a treatment-induced complication, a coincidence, or an increased susceptibility to secondary malignancies due to the malignant process itself.